
VYANT BIO INC (VYNT) Fundamental Analysis & Valuation
NASDAQ:VYNT • US92942V2088
Current stock price
0.26 USD
-0.08 (-23.51%)
At close:
0.2211 USD
-0.04 (-14.96%)
After Hours:
This VYNT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. VYNT Profitability Analysis
1.1 Basic Checks
- In the past year VYNT has reported negative net income.
- VYNT had a negative operating cash flow in the past year.
1.2 Ratios
- VYNT has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for VYNT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. VYNT Health Analysis
2.1 Basic Checks
- VYNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for VYNT has been increased compared to 1 year ago.
- Compared to 1 year ago, VYNT has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -11.95, we must say that VYNT is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -11.95, VYNT is doing worse than 80.35% of the companies in the same industry.
- VYNT has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- VYNT has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.95 |
ROIC/WACCN/A
WACC8.02%
2.3 Liquidity
- A Current Ratio of 3.14 indicates that VYNT has no problem at all paying its short term obligations.
- The Current ratio of VYNT (3.14) is worse than 69.89% of its industry peers.
- A Quick Ratio of 3.13 indicates that VYNT has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.13, VYNT is doing worse than 68.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.13 |
3. VYNT Growth Analysis
3.1 Past
- The earnings per share for VYNT have decreased strongly by -101.61% in the last year.
- VYNT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.19%.
- The Revenue for VYNT have been decreasing by -53.03% on average. This is quite bad
EPS 1Y (TTM)-101.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-260.59%
Revenue 1Y (TTM)-86.19%
Revenue growth 3Y-55%
Revenue growth 5Y-53.03%
Sales Q2Q%-95.99%
3.2 Future
- VYNT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.54% yearly.
- Based on estimates for the next years, VYNT will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y37.93%
EPS Next 2Y19.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. VYNT Valuation Analysis
4.1 Price/Earnings Ratio
- VYNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYNT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- VYNT's earnings are expected to grow with 19.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.54%
EPS Next 3YN/A
5. VYNT Dividend Analysis
5.1 Amount
- No dividends for VYNT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VYNT Fundamentals: All Metrics, Ratios and Statistics
0.26
-0.08 (-23.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2023-05-15
Earnings (Next)08-14 2023-08-14
Inst Owners0%
Inst Owner Change0%
Ins Owners7.2%
Ins Owner Change0%
Market Cap1.63M
Revenue(TTM)666.00K
Net Income(TTM)-22.69M
Analysts82.86
Price Target5.1 (1861.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.73%
Min EPS beat(2)-15.91%
Max EPS beat(2)17.37%
EPS beat(4)1
Avg EPS beat(4)-31.33%
Min EPS beat(4)-96.08%
Max EPS beat(4)17.37%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)99.64%
Min Revenue beat(2)87.91%
Max Revenue beat(2)111.38%
Revenue beat(4)2
Avg Revenue beat(4)44.8%
Min Revenue beat(4)-19.12%
Max Revenue beat(4)111.38%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-46.01%
EPS NY rev (3m)-77.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.16 | ||
| P/tB | 0.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.91
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-2.28
FCFYN/A
OCF(TTM)-2.18
OCFYN/A
SpS0.11
BVpS1.58
TBVpS1.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 118.2% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | -11.95 |
F-Score2
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)73.94%
Cap/Depr(5y)45.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-260.59%
EPS Next Y37.93%
EPS Next 2Y19.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-86.19%
Revenue growth 3Y-55%
Revenue growth 5Y-53.03%
Sales Q2Q%-95.99%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.49%
OCF growth 3YN/A
OCF growth 5YN/A
VYANT BIO INC / VYNT Fundamental Analysis FAQ
What is the ChartMill fundamental rating of VYANT BIO INC (VYNT) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VYNT.
What is the valuation status for VYNT stock?
ChartMill assigns a valuation rating of 3 / 10 to VYANT BIO INC (VYNT). This can be considered as Overvalued.
Can you provide the profitability details for VYANT BIO INC?
VYANT BIO INC (VYNT) has a profitability rating of 0 / 10.
What is the earnings growth outlook for VYANT BIO INC?
The Earnings per Share (EPS) of VYANT BIO INC (VYNT) is expected to grow by 37.93% in the next year.